AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26756882 — intervention group
Group type: EXPERIMENTAL
Intervention: Cantilevered RBFPD (CL2)
Number of subjects: 28
Study 26756882 — intervention group
Group type: COMPARATOR
Intervention: Fixed-fixed RBFPD (FF3)
Number of subjects: 28
Study 24179984 — intervention group
Group type: EXPERIMENTAL
Intervention: Solvent removal using paper point and light-curing methods (cocuring for 40 s, adhesive cured for 20 s, adhesive cured for 40 s, intracanal tip for 20 s)
Number of subjects: 80
Study 24179984 — intervention group
Group type: COMPARATOR
Intervention: Solvent removal using air-drying method and light-curing methods (cocuring for 40 s, adhesive cured for 20 s, adhesive cured for 40 s, intracanal tip for 20 s)
Number of subjects: 80
Study 22092997 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zinc sulphate (3 × 200 mg/day)
Number of subjects: 14
Study 22092997 — intervention group
Group type: COMPARATOR
Intervention: Control group (4 patients without treatment)
Number of subjects: 14
Study 20858692 — intervention group
Group type: EXPERIMENTAL
Intervention: Current practice plus information aid (personal interview with a physician using a navigable compact disc and a take-home booklet)
Number of subjects: 120
Study 20858692 — intervention group
Group type: COMPARATOR
Intervention: Current practice (diagnosis disclosure)
Number of subjects: 120
Study 19102147 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder-elbow elastic band immobilization and functional exercise
Number of subjects: 75
Study 19102147 — intervention group
Group type: COMPARATOR
Intervention: Forearm-suspending band immobilization and functional exercise therapy
Number of subjects: 75
Study 16907901 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzocaine/tyrothricin sucking lozenges with conscious sedation
Number of subjects: 174
Study 16907901 — intervention group
Group type: COMPARATOR
Intervention: Conscious sedation alone
Number of subjects: 174
Study 12521968 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment and intervention
Number of subjects: 274
Study 12521968 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (control group)
Number of subjects: 274
Study 11375586 — intervention group
Group type: EXPERIMENTAL
Intervention: Minilaparoscopy (ML)
Number of subjects: 104
Study 11375586 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopy (CL)
Number of subjects: 104
Study 10322831 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of Xuefu Zhuyu decoction and move stripe field radiation
Number of subjects: 0
Study 10322831 — intervention group
Group type: COMPARATOR
Intervention: Placebo and radiotherapy
Number of subjects: 0
Study 8435382 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide (20 mg/day)
Number of subjects: 7
Study 8435382 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (50 mg/day)
Number of subjects: 7
Study 3304118 — intervention group
Group type: EXPERIMENTAL
Intervention: terodiline (50 mg/d)
Number of subjects: 20
Study 3304118 — intervention group
Group type: EXPERIMENTAL
Intervention: emepronium (600 mg/d)
Number of subjects: 20
Study 3304118 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 28952873 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-determination theory-based dance program
Number of subjects: 35
Study 28952873 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-determination theory-based walking program
Number of subjects: 35
Study 28952873 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 35
Study 28533679 — intervention group
Group type: COMPARATOR
Intervention: rosuvastatin 20 mg alone
Number of subjects: 13
Study 28533679 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg plus EGCG 300 mg on Day 4
Number of subjects: 13
Study 28533679 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg plus EGCG 300 mg on Day 15
Number of subjects: 13
Study 25644997 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted recruitment letter with health risk information specific to their racial/ethnic group (n = 216)
Number of subjects: 445
Study 25644997 — intervention group
Group type: COMPARATOR
Intervention: Standard letter with risk information for the general population (n = 229)
Number of subjects: 445
Study 24135131 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic version of Featback (psychoeducation and fully automated monitoring and feedback system)
Number of subjects: 0
Study 24135131 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic version of Featback with infrequent support (weekly e-mail, chat, or Skype support from a coach)
Number of subjects: 0
Study 24135131 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic version of Featback with frequent support (three times a week e-mail, chat, or Skype support from a coach)
Number of subjects: 0
Study 24135131 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 0
Study 21164127 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% albumin (ALB)
Number of subjects: 434
Study 21164127 — intervention group
Group type: COMPARATOR
Intervention: saline (placebo)
Number of subjects: 434
Study 18234132 — intervention group
Group type: EXPERIMENTAL
Intervention: Intentional weight loss
Number of subjects: 11
Study 18234132 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle interventions (intentional weight loss)
Number of subjects: 11
Study 18234132 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 11
Study 17163254 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronic acid (400 mg/day for 24 weeks)
Number of subjects: 14
Study 17163254 — intervention group
Group type: COMPARATOR
Intervention: Control (no etidronic acid therapy)
Number of subjects: 14
Study 12665756 — intervention group
Group type: EXPERIMENTAL
Intervention: Peppermint oil solution administered intraluminally
Number of subjects: 100
Study 12665756 — intervention group
Group type: COMPARATOR
Intervention: Hyoscine‐N‐butylbromide injection
Number of subjects: 100
Study 12665756 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution administered intraluminally
Number of subjects: 100
Study 12665756 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution administered intramuscularly
Number of subjects: 100
Study 10719808 — intervention group
Group type: EXPERIMENTAL
Intervention: Late addition of G-CSF (250 microg) from day 8 after cyclophosphamide (4 g/m2)
Number of subjects: 30
Study 10719808 — intervention group
Group type: COMPARATOR
Intervention: Early addition of G-CSF (250 microg) from day 2 after cyclophosphamide (4 g/m2)
Number of subjects: 30
Study 10719808 — intervention group
Group type: EXPERIMENTAL
Intervention: Late addition of G-CSF
Number of subjects: 30
Study 10719808 — intervention group
Group type: COMPARATOR
Intervention: Early addition of G-CSF
Number of subjects: 30
Study 10719808 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 9196130 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan (1.5 mg/m2 as a 30‐minute infusion daily for 5 days every 21 days)
Number of subjects: 226
Study 9196130 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (175 mg/m2 infused over 3 hours every 21 days)
Number of subjects: 226
Study 30852486 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine Zhiyi decoction combined with acupuncture
Number of subjects: 84
Study 30852486 — intervention group
Group type: COMPARATOR
Intervention: Traditional Chinese medicine Zhiyi decoction
Number of subjects: 84
Study 30852486 — intervention group
Group type: COMPARATOR
Intervention: Control group (Traditional Chinese medicine Zhiyi decoction)
Number of subjects: 84
Study 30852486 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group (Zhiyi decoction + acupuncture)
Number of subjects: 84
Study 30852486 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 84
Study 28883543 — intervention group
Group type: EXPERIMENTAL
Intervention: New Nordic Diet (NND) high in fiber/whole grain
Number of subjects: 62
Study 28883543 — intervention group
Group type: COMPARATOR
Intervention: Average Danish Diet (ADD)
Number of subjects: 62
Study 28883543 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of responsiveness to diets
Number of subjects: 62
Study 26877998 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanoplasty without malleus lifting
Number of subjects: 30
Study 26877998 — intervention group
Group type: COMPARATOR
Intervention: Tympanoplasty with malleus lifting
Number of subjects: 30
Study 24865795 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Coping Skills Training (PCST)
Number of subjects: 256
Study 24865795 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 256
Study 22480387 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine-fluoxetine combination (6/50-18/50 mg/d)
Number of subjects: 205
Study 22480387 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (50 mg/d)
Number of subjects: 205
Study 22480387 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine (6-18 mg/d)
Number of subjects: 205
Study 18465716 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia (TA)
Number of subjects: 59
Study 18465716 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-Tenon block (STB)
Number of subjects: 59
Study 16973303 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionation (used in 41 patients, 73%)
Number of subjects: 56
Study 16973303 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation (used in 15 patients, 27%)
Number of subjects: 56
Study 16973303 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionation
Number of subjects: 56
Study 16973303 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation
Number of subjects: 56
Study 12760627 — intervention group
Group type: EXPERIMENTAL
Intervention: Utterance format variation
Number of subjects: 0
Study 12760627 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 10644101 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-soluble contrast material (WSCM)
Number of subjects: 666
Study 10644101 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil-soluble contrast material (OSCM)
Number of subjects: 666
Study 10644101 — intervention group
Group type: EXPERIMENTAL
Intervention: Both OSCM and WSCM
Number of subjects: 666
Study 10644101 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 666
Study 9242302 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccades toward visual single- and double-step stimuli
Number of subjects: 0
Study 8304889 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexoprenaline
Number of subjects: 63
Study 8304889 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine
Number of subjects: 63
Study 8304889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 3653970 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive patients
Number of subjects: 107
Study 3653970 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive patients (women)
Number of subjects: 107
Study 3653970 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive patients (blacks)
Number of subjects: 107
Study 29396785 — intervention group
Group type: EXPERIMENTAL
Intervention: LESSOP-DN
Number of subjects: 99
Study 29396785 — intervention group
Group type: COMPARATOR
Intervention: MLDN
Number of subjects: 99
Study 27472280 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG revaccination
Number of subjects: 0
Study 27472280 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 25691114 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of WHO surgical safety checklist (Rc arm)
Number of subjects: 700
Study 25691114 — intervention group
Group type: COMPARATOR
Intervention: Control group (Rn arm)
Number of subjects: 700
Study 24325105 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses Ulinastatin (20,000 U/kg)
Number of subjects: 90
Study 24325105 — intervention group
Group type: EXPERIMENTAL
Intervention: Low doses Ulinastatin (5,000 U/kg)
Number of subjects: 90
Study 24325105 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 90
Study 20828230 — intervention group
Group type: EXPERIMENTAL
Intervention: Truth effect measured by rating previously seen statements as true or false.
Number of subjects: 74
Study 20828230 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiarity with opposite sets of statements.
Number of subjects: 74
Study 18405789 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg
Number of subjects: 36
Study 18405789 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin 50 mg
Number of subjects: 36
Study 18405789 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin 100 mg
Number of subjects: 36
Study 18405789 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin 200 mg
Number of subjects: 36
Study 18405789 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin 400 mg
Number of subjects: 36
Study 18405789 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin 800 mg
Number of subjects: 36
Study 18405789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 17142537 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 0
Study 17142537 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting beta agonists
Number of subjects: 0
Study 17142537 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialty care
Number of subjects: 0
Study 12945220 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 547
Study 10714531 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic spinal manipulation aimed at correcting SI-joint dysfunction
Number of subjects: 28
Study 10714531 — intervention group
Group type: COMPARATOR
Intervention: No joint manipulation (Control)
Number of subjects: 28
Study 10714531 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic spinal manipulation
Number of subjects: 28
Study 9176996 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg (+)S-ibuprofen arginine
Number of subjects: 7
Study 9176996 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg (−)R-ibuprofen arginine
Number of subjects: 7
Study 9176996 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg racemic ibuprofen arginine
Number of subjects: 7
Study 9176996 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg (+)S-ibuprofen arginine and 400 mg (−)R-ibuprofen arginine
Number of subjects: 7
Study 9176996 — intervention group
Group type: EXPERIMENTAL
Intervention: (−)R-ibuprofen arginine
Number of subjects: 7
Study 1585758 — intervention group
Group type: EXPERIMENTAL
Intervention: Micanol with thorough application information
Number of subjects: 29
Study 1585758 — intervention group
Group type: COMPARATOR
Intervention: Micanol with standard patient information
Number of subjects: 29
Study 4037034 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg nadolol
Number of subjects: 40
Study 4037034 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg nadolol
Number of subjects: 40
Study 4037034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29633043 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic energy-based surgical device (n=20)
Number of subjects: 40
Study 29633043 — intervention group
Group type: COMPARATOR
Intervention: Monopolar energy-based surgical device (n=20)
Number of subjects: 40
Study 28029312 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP88 risk score
Number of subjects: 995
Study 28029312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 995
Study 28029312 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 995
Study 28029312 — intervention group
Group type: EXPERIMENTAL
Intervention: TC model
Number of subjects: 995
Study 28029312 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined SNP88 and TC model
Number of subjects: 995
Study 26678637 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6)
Number of subjects: 6187
Study 26678637 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 6187
Study 26678637 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 (after adjustment for cardiac and renal biomarkers)
Number of subjects: 6187
Study 26678637 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP (after adjustment for cardiac and renal biomarkers)
Number of subjects: 6187
Study 26678637 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 (added to CHA2DS2-VASc risk score)
Number of subjects: 6187
Study 26678637 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen
Number of subjects: 6187
Study 24524601 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 20 mg qn or other statin equivalent to 20 mg atorvastatin
Number of subjects: 104
Study 24524601 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin plus bezafibrate 200 mg bid
Number of subjects: 104
Study 24524601 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study 24524601 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 104
Study 21037270 — intervention group
Group type: EXPERIMENTAL
Intervention: Written action plan adherence
Number of subjects: 252
Study 18694978 — intervention group
Group type: EXPERIMENTAL
Intervention: Load group (priming dose of 0.07 units of regular insulin per kg body weight followed by 0.07 unit x kg(‐1) x h(‐1) i.v.)
Number of subjects: 37
Study 18694978 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice no load group (infusion of regular insulin of 0.14 x kg(‐1) x h(‐1) without a loading dose)
Number of subjects: 37
Study 18694978 — intervention group
Group type: COMPARATOR
Intervention: No load group (infusion of regular insulin of 0.07 unit . kg body weight(‐1) x h(‐1) without a loading dose)
Number of subjects: 37
Study 18694978 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of all groups
Number of subjects: 37
Study 16534238 — intervention group
Group type: EXPERIMENTAL
Intervention: OKT3 therapy in addition to tacrolimus
Number of subjects: 50
Study 16534238 — intervention group
Group type: COMPARATOR
Intervention: Control cohort (cadaveric renal transplant patients from 1995)
Number of subjects: 50
Study 12751506 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine iontophoresis (4% lidocaine, 4 ml for 10 min)
Number of subjects: 30
Study 12751506 — intervention group
Group type: COMPARATOR
Intervention: Local infiltration of lidocaine (1% lidocaine, 1 ml)
Number of subjects: 30
Study 10687338 — intervention group
Group type: EXPERIMENTAL
Intervention: MS:DM (morphine sulfate and dextromethorphan hydrobromide)
Number of subjects: 321
Study 10687338 — intervention group
Group type: EXPERIMENTAL
Intervention: MS:DM
Number of subjects: 321
Study 10687338 — intervention group
Group type: COMPARATOR
Intervention: MS
Number of subjects: 321
Study 9494946 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (0, 7, 14, or 21 mg doses)
Number of subjects: 66
Study 9494946 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg nicotine)
Number of subjects: 66
Study 9494946 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine
Number of subjects: 66
Study 9494946 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine and abstinence from smoking
Number of subjects: 66
Study 8444088 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg at night
Number of subjects: 443
Study 8444088 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg twice daily
Number of subjects: 443
Study 8444088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 443
Study 3023556 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cisplatin (120 mg/m2 day 1) + etoposide (120 mg/m2 days 3, 5, and 7)
Number of subjects: 241
Study 3023556 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose cisplatin (60 mg/m2 day 1) + etoposide (120 mg/m2 days 3, 5, and 7)
Number of subjects: 241
Study 31275576 — intervention group
Group type: EXPERIMENTAL
Intervention: KOKO Plus (KP)
Number of subjects: 1273
Study 28604990 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic needle tip positioning (DNTP)
Number of subjects: 40
Study 28604990 — intervention group
Group type: COMPARATOR
Intervention: Palpation technique
Number of subjects: 40
Study 26233916 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg daily)
Number of subjects: 193
Study 26233916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 22878351 — intervention group
Group type: EXPERIMENTAL
Intervention: CAM2
Number of subjects: 15
Study 22878351 — intervention group
Group type: COMPARATOR
Intervention: NAL‐NL2
Number of subjects: 15
Study 21474529 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevention intervention (5 sessions)
Number of subjects: 57
Study 21474529 — intervention group
Group type: COMPARATOR
Intervention: Health promotion intervention (5 sessions)
Number of subjects: 57
Study 21474529 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevention intervention
Number of subjects: 57
Study 21474529 — intervention group
Group type: COMPARATOR
Intervention: Health promotion intervention
Number of subjects: 57
Study 19703381 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium prescribed
Number of subjects: 84
Study 19703381 — intervention group
Group type: COMPARATOR
Intervention: No lithium prescribed
Number of subjects: 84
Study 19703381 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall ECT treatment
Number of subjects: 84
Study 17276431 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin (1 microg/kg i.v. bolus)
Number of subjects: 35
Study 15521161 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 postcards
Number of subjects: 8881
Study 15521161 — intervention group
Group type: COMPARATOR
Intervention: 1 postcard
Number of subjects: 8881
Study 15521161 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 postcard + tool kit
Number of subjects: 8881
Study 15521161 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 postcards + tool kit
Number of subjects: 8881
Study 14742041 — intervention group
Group type: EXPERIMENTAL
Intervention: Asynchronous electronic small groups
Number of subjects: 0
Study 14742041 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face small groups
Number of subjects: 0